Lipid-lowering therapies in peripheral artery disease: A review
N Skeik, ME Nowariak, JE Smith… - Vascular …, 2021 - journals.sagepub.com
Peripheral artery disease (PAD) is estimated to affect approximately 8.5 million individuals in
the US above the age of 40, and is associated with significant morbidity, mortality, and …
the US above the age of 40, and is associated with significant morbidity, mortality, and …
Lipid-lowering treatment in peripheral artery disease
Highlights•Peripheral artery disease (PAD) is characterized by increased cardiovascular
risk.•Statins remain the first-line lipid-lowering therapy to treat PAD patients.•Statins …
risk.•Statins remain the first-line lipid-lowering therapy to treat PAD patients.•Statins …
The current evidence for lipid management in patients with lower extremity peripheral artery disease: what is the therapeutic target?
JA Rymer, RV Swaminathan, AW Aday… - Current Cardiology …, 2021 - Springer
Abstract Purpose of Review There is a lack of consistency among the ACC/AHA and ESC
Guidelines on the treatment of patients with lower extremity PAD to a targeted LDL-c level. A …
Guidelines on the treatment of patients with lower extremity PAD to a targeted LDL-c level. A …
[HTML][HTML] Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease
Patients with peripheral arterial disease (PAD) are at very high risk of cardiovascular events,
but risk factor management is usually suboptimal. This Joint Task Force from the European …
but risk factor management is usually suboptimal. This Joint Task Force from the European …
Peripheral Artery Disease: Past and Future
MM McDermott - Circulation, 2024 - Am Heart Assoc
In the past 50 years, randomized clinical trials demonstrated benefits of intensive low-
density lipoprotein–lowering therapy for people with cardiovascular disease, including in …
density lipoprotein–lowering therapy for people with cardiovascular disease, including in …
Use of statins in patients with peripheral artery disease
E Corrado, A Mignano, G Coppola - Trends in Cardiovascular Medicine, 2020 - Elsevier
Atherosclerotic peripheral artery disease (PAD) is a growing health issue that affects more
than 200 million individuals worldwide, conferring a high risk of cardiovascular events and …
than 200 million individuals worldwide, conferring a high risk of cardiovascular events and …
[HTML][HTML] Dyslipidemia and peripheral arterial disease
A Yadav, V Sawant, VS Bedi, K Yadav - Indian Heart Journal, 2024 - Elsevier
Peripheral arterial disease (PAD) affects 12% of adult population and is increasing globally
and in India. Peripheral arterial disease when associated with atherosclerosis in two or more …
and in India. Peripheral arterial disease when associated with atherosclerosis in two or more …
Effectiveness of blood lipid management in patients with peripheral artery disease
CN Hess, CP Cannon, JA Beckman… - Journal of the American …, 2021 - jacc.org
Background Low-density lipoprotein cholesterol (LDL-C) is associated with heightened risk
of major adverse cardiovascular events (MACE) and major adverse limb events (MALE) in …
of major adverse cardiovascular events (MACE) and major adverse limb events (MALE) in …
Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further …
MP Bonaca, P Nault, RP Giugliano, AC Keech… - Circulation, 2018 - Am Heart Assoc
Background: The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor
evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the …
evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the …
[HTML][HTML] Lipid-lowering therapy in patients with peripheral artery disease
I Crismaru, CC Diaconu - EJ. ESC Counc. Cardiol. Pract, 2015 - escardio.org
Peripheral artery disease (PAD) is a manifestation of systemic atherosclerosis and is
associated with high mortality due to cardiovascular events. As lipid-lowering therapy has …
associated with high mortality due to cardiovascular events. As lipid-lowering therapy has …